Linagliptin - diabetes safely controlled from the very start

Linagliptin approved for type 2 diabetes.

Linagliptin for the treatment of type 2 diabetes (pharmacokinetic evaluation).

INTRODUCTION Dipeptidyl peptidase-4 (DPP-4) inhibitors offer new options for the management of type 2 diabetes (T2DM). The novel compound linagliptin has important different pharmacokinetic (PK) properties, when compared with previously commercialized DPP-4 inhibitors, which may offer some advantages in clinical practice. Linagliptin has a unique PK/pharmacodynamic (PD) profile and is the first...

Effects of Adding Linagliptin to Basal Insulin Regimen for Inadequately Controlled Type 2 Diabetes

OBJECTIVE To evaluate the efficacy and long-term safety of linagliptin added to basal insulins in type 2 diabetes inadequately controlled on basal insulin with or without oral agents. RESEARCH DESIGN AND METHODS A total of 1,261 patients (HbA1c ≥7.0% [53 mmol/mol] to ≤10.0% [86 mmol/mol]) on basal insulin alone or combined with metformin and/or pioglitazone were randomized (1:1) to double-bli...

Can Type 1 Diabetes patients safely fast during Ramadan?

The issue whether people with Type 1 Diabetes can safely fast during Ramadan has been the subject of quite a few debates over the years. Had it been a simple "yes" or "no" issue, there would have been no reason to debate. However, like a lot of other topics in medical management, this particular subject overlaps both the science and the art of medicine.

Linagliptin: from bench to bedside

PURPOSE The nature of biomedical research affords a broad range of investigational topics at the preclinical stage, not all of which may be explored in subsequent clinical studies. To provide a comprehensive perspective on the physiologic effects of the dipeptidyl peptidase-4 inhibitor linagliptin, this review will discuss the results of both preclinical and clinical research, summarizing data ...